Hims & Hers Health (HIMS, Financial) shares jumped 18% as of 11 AM today after the company announced its next big move—at-home lab testing. This expansion, made possible by acquiring Sigmund NJ LLC, marketed as Trybe Labs, positions Hims & Hers to take a deeper dive into personalized healthcare. Customers will soon be able to test for key health markers like hormone levels, cardiac risk, and thyroid function from home—without traditional needles. This move strengthens the company's competitive edge in digital health, with AI-driven insights enhancing early disease detection and treatment precision.

The acquisition broadens Hims & Hers' offerings, integrating AI-powered tools like MedMatch to refine personalized treatment recommendations. The company plans to use de-identified lab data to accelerate its AI development, getting closer to delivering a seamless, tech-driven healthcare experience. By removing the barriers of traditional medical testing, Hims & Hers is tapping into a growing market of consumers looking for convenience, affordability, and data-backed treatment options.

With the deal closed and rollout expected over the next year, investors are betting big on Hims & Hers' long-term potential in telehealth. The company is proving it's not just a player in the digital health space—it's shaping the future of personalized medicine. If this expansion delivers as expected, Hims & Hers could solidify itself as a market leader in the rapidly growing at-home diagnostics sector.